Compare · BLCO vs STAA
BLCO vs STAA
Side-by-side comparison of Bausch + Lomb Corporation (BLCO) and STAAR Surgical Company (STAA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BLCO and STAA operate in Ophthalmic Goods (Health Care), so they compete in similar markets.
- BLCO is the larger of the two at $6.16B, about 5.3x STAA ($1.16B).
- BLCO has been more active in the news (23 items in the past 4 weeks vs 11 for STAA).
- STAA has more recent analyst coverage (25 ratings vs 19 for BLCO).
- Company
- Bausch + Lomb Corporation
- STAAR Surgical Company
- Price
- -
- -
- Market cap
- $6.16B
- $1.16B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Ophthalmic Goods
- Ophthalmic Goods
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 23
- 11
- Recent ratings
- 19
- 25
Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in Canada and internationally. It operates through three segments: Vision Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that cover the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions. It offers intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone intraocular lenses, as well as preloaded injectors for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. STAAR Surgical Company markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, and Italy. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
Latest BLCO
- Bausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial Results
- Director Trebbi Barbara was granted 11,776 shares (SEC Form 4)
- SEC Form 3 filed by new insider Trebbi Barbara
- Director Paul Laurence E was granted 11,776 shares (SEC Form 4)
- SEC Form 3 filed by new insider Paul Laurence E
- Director Chersi Robert J was granted 11,776 shares (SEC Form 4)
- SEC Form 3 filed by new insider Chersi Robert J
- New insider Appio Thomas claimed ownership of 27,583 shares (SEC Form 3)
- SVP, Controller and CAO Munsch Frederick sold $887,662 worth of shares (52,900 units at $16.78), decreasing direct ownership by 54% to 45,831 units (SEC Form 4)
- Amendment: SEC Form 8-K/A filed by Bausch + Lomb Corporation
Latest STAA
- Chief Development Officer Michna Magda exercised 6,599 shares at a strike of $4.36 and covered exercise/tax liability with 3,356 shares, increasing direct ownership by 9% to 41,343 units (SEC Form 4)
- Chief Financial Officer & EVP Andrews Deborah J converted options into 5,233 shares and covered exercise/tax liability with 2,662 shares, increasing direct ownership by 7% to 38,910 units (SEC Form 4)
- President and CEO Foust Warren converted options into 10,997 shares and covered exercise/tax liability with 5,595 shares, increasing direct ownership by 11% to 95,816 units (SEC Form 4)
- SEC Form 10-Q filed by STAAR Surgical Company
- STAAR Surgical Company filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- STAAR Surgical Reports Second Quarter 2026 Results
- STAAR Surgical Company filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- President and CEO Foust Warren converted options into 20,787 shares and covered exercise/tax liability with 10,576 shares, increasing direct ownership by 13% to 86,556 units (SEC Form 4)
- Chief Financial Officer & EVP Andrews Deborah J converted options into 34,742 shares and covered exercise/tax liability with 17,056 shares, increasing direct ownership by 95% to 36,339 units (SEC Form 4)
- STAAR Surgical Appoints Warren Foust as President and Chief Executive Officer